Events & Presentations
Upcoming Events
Date | Event Details | Remind Me |
---|---|---|
Apr 3 - Apr 4, 2023
|
7th Complement UK Training Course and Symposium
|
Archived Events
Date | Event Details |
---|---|
Mar 8, 2023 10:30 AM EST
|
43rd Annual Cowen Health Care Conference
|
Feb 6, 2023 4:30 PM EST
|
Arrowhead Pharmaceuticals 2023 First Quarter Results
Prepared Remarks 265 KB
|
Jan 9, 2023 11:15 AM EST
|
41st Annual J.P. Morgan Healthcare Conference
View Presentation 3 MB
|
Jan 9, 2023 8:30 AM EST
|
Fazirsiran Phase 2 SEQUOIA Study Webcast
View Presentation 1.9 MB
|
Dec 1, 2022 11:20 AM EST
|
Evercore ISI 5th Annual HealthCONx Conference
Presenter: Christopher Anzalone, Ph.D., President and CEO
|
Nov 30, 2022 2:00 PM EST
|
Piper Sandler 34th Annual Healthcare Conference
Presenter: Christopher Anzalone, Ph.D., President and CEO
|
Nov 28, 2022 4:30 PM EST
|
Arrowhead Pharmaceuticals Fiscal 2022 Year End Results
Prepared Remarks 292.1 KB
|
Nov 9, 2022 10:00 AM EST
|
Virtual ARO-APOC3 and ARO-ANG3 Investor Event
View Presentation 8 MB
|
Nov 5 - Nov 7, 2022
|
American Heart Association (AHA) Scientific Sessions 2022
AHA 2022 AROAPOC3-2001 595.8 KB
AHA 2022 AROANG3-2001 573.5 KB
Title: ARO-ANG3, an Investigational RNAi Therapeutic, Decreases Serum Angiopoietin-Like Protein 3, Triglycerides, and Cholesterol in Patients With Mixed Dyslipidemia Title: ARO-APOC3, an Investigational RNAi Therapeutic, Decreases Serum Apolipoprotein C3, Triglyceride, and Non-HDL-C Concentrations While Increasing HDL-C in Patients With Severe Hypertriglyceridemia |
Oct 4, 2022 2:00 PM EDT
|
Chardan’s 6th Annual Genetic Medicines Summit
Type: Fireside chat presentation
Presenter: Vincent Anzalone, Vice President Finance and Investor Relations, Arrowhead Pharmaceuticals |